Press Releases

03.13.2023

Pfizer Invests $43 Billion to Battle Cancer

03.10.2023

Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval

03.01.2023

Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years

02.28.2023

Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults

02.27.2023

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

02.24.2023

Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster

02.22.2023

Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance

02.21.2023

U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review

02.16.2023

Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study

02.16.2023

Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults

02.10.2023

FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)

02.09.2023

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference